The combination of cagrilintide and semaglutide, marketed as CagriSema, provides synergistic benefits for weight loss and metabolic health by targeting complementary hormonal pathways.
 Cagrilintide, a synthetic amylin analog, enhances satiety and slows gastric emptying via brainstem pathways, while semaglutide, a GLP-1 receptor agonist, reduces appetite, suppresses glucagon, and improves insulin sensitivity.
 Clinical trials, including the REDEFINE studies, show that this combination leads to substantial weight loss—up to 22.7% in individuals without type 2 diabetes and 15.7% in those with the condition—approaching outcomes seen with bariatric surgery.
 Additionally, patients experience significant improvements in HbA1c, blood pressure, lipids, and inflammation markers, with 87.7% of prediabetic individuals achieving normoglycemia and 73.5% of those with type 2 diabetes reaching HbA1c ≤6.5%.
 The once-weekly subcutaneous injection format improves adherence, and the treatment is generally well-tolerated, with gastrointestinal side effects like nausea being common but manageable.